1,059 trials (keyword fallback)
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
Glaucoma, Neovascular
Primary: Change in Intraocular Pressure (IOP) From Baseline to Week 1 — -8.3 mmHg — p=0.0004
HIV · Inflammation · Atherosclerosis
Primary: Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment — -0.126; 0.026 TBR
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Rhegmatogenous Retinal Detachment - Macula Off
Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants
Multiple Sclerosis
Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
Exudative Age Related Macular Degeneration
Primary: Vitreal VEGF Levels. — 735.48; 626.09; 141.11; 235.81 pg/ml
Vitreous Hemorrhage · Proliferative Diabetic Retinopathy
Primary: Treatment or "Failure" Defined as Vitrectomy — 12; 17 percentage of participants — p=0.37
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
Diabetic Macular Edema
Primary: Number of Participants With Intraocular Inflammation — 6; 10 Participants
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL